Stereotaxis Stock Discussion

$Stereotaxis (STXS.US)$ Stereotaxis Announces That Physicians At The Hospital Da Luz In Lisbon, Portugal Have Successfully Treated The First Patients Using The Advanced Genesis Robotic Magnetic Navigation System
Benzinga· 3 mins ago

$Stereotaxis (STXS.US)$
Onward!

$Stereotaxis (STXS.US)$ Benzinga· 1 min ago
Stereotaxis Announces University Of Kansas Medical Center Physicians Have Treated The First Patients Using The Company's Genesis Robotic Magnetic Navigation System

$Stereotaxis (STXS.US)$ Stereotaxis Robotic Technology to be Featured during Heart Rhythm Society’s HRX Congress! September 5th to 7th

$Stereotaxis (STXS.US)$
Stereotaxis Achieves CE Mark in Europe and Submits 510(k) in the US for Next Generation Robotic System GenesisX
Stereotaxis (NYSE: STXS), a leader in surgical robotics for minimally invasive endovascular intervention, has achieved significant milestones for its next-generation robotic system, GenesisX. The company has obtained CE mark in Europe and submitted a 510(k) application to the FDA in the US. GenesisX builds upon the established benefits of Robotic Magnetic Nav...

$Stereotaxis (STXS.US)$
Penn Presbyterian Medical Center Becomes First Hospital in the Northeast to Adopt Advanced Robotic Technology for Heart Treatment

$Stereotaxis (STXS.US)$
Stereotaxis Receives CE Mark Recertification Under EU’s MDR Regulatory Framework

$Stereotaxis (STXS.US)$
NEWS
First Heart Rhythm Patients in Southern Italy Treated with Advanced Robotic Technology

$Stereotaxis (STXS.US)$
NEWS
Stereotaxis Reports 2024 First Quarter Financial Results
Stereotaxis (NYSE: STXS), a leader in surgical robotics for minimally invasive endovascular intervention, reported financial results for Q1 2024, ending March 31. Revenue grew 5% YoY to $6.9M, with system revenue at $2.6M and recurring revenue at $4.3M. Gross margin was 58%. Operating expenses were $8.7M, including $2.6M in non-cash stock compensation. Adjusted operating expenses were $6.1M, down from $6.9M YoY....

$Stereotaxis (STXS.US)$
NEWS
Stereotaxis Announces Definitive Agreement to Acquire Access Point Technologies
Stereotaxis (NYSE: STXS), a leader in surgical robotics for minimally invasive endovascular intervention, announced a definitive agreement to acquire Access Point Technologies EP (APT). APT, based in Minnesota, develops electrophysiology catheters used in cardiac ablation procedures. This acquisition enhances Stereotaxis' catheter development, manufacturing capabilities, and provides comme...